Case number 2023-2032
Astellas Pharma, Inc. v. Sandoz Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Sep 22, 2024 | 0 | ASTELLAS PHARMA, INC. v. SANDOZ INC. [OPINION] [precedential] (0) |
| Aug 7, 2024 | 89 | Submitted after ORAL ARGUMENT to Panel: Lourie, Circuit Judge; Prost, Circuit Judge and Reyna, Circuit Judge.Arguing counsel: Mr. Paul Whitfield Hughes, III for Astellas Pharma, Inc., Astellas Ireland Co., Ltd. and Astellas Pharma Global Development, Inc. and Mr. William R. Zimmerman for Lupin Pharmaceuticals, Inc., Lupin Ltd., Lek Pharmaceuticals, d.d., Sandoz Inc., Zydus Lifesciences Ltd., and Zydus Pharmaceuticals (USA) Inc.Oral Argument Audio available here. [1023377] [JCP] [Entered: 08/07/2024 12:06 PM] (0) |
| Jun 21, 2024 | 88 | Response to notice of oral argument from Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/21/2024 by email. [1012647] [23-2032] [William Zimmerman] [Entered: 06/21/2024 04:41 PM] (1) |
| Jun 21, 2024 | 87 | Response to notice of oral argument from Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 06/21/2024 by email. [1012561] [23-2032] [Paul Hughes] [Entered: 06/21/2024 03:07 PM] (1) |
| Jun 21, 2024 | 86 | NOTICE OF ORAL ARGUMENT. Panel: 2408B. Case scheduled August 7, 2024. Response to Notice of Oral Argument due: 07/05/2024. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [1012467] [MVH] [Entered: 06/21/2024 01:27 PM] (2) |
| May 9, 2024 | 85 | ORDER ECF No. [76] is granted. ECF Nos. [74] and [75] are accepted for filing as the movants' nonconfidential and confidential versions of their opposition, respectively. Service as of this date by the Clerk of Court. [1003135] [NL] [Entered: 05/09/2024 10:54 AM] (2) |
| May 9, 2024 | 84 | ORDER The temporary injunction imposed by the court's April 22, 2024 order (ECF No. [73]) is lifted. The motion [71] for an injunction pending appeal is denied. ECF No. [70]'s request to expedite is granted to the extent that the case will be placed on the August 2024 oral argument calendar. (Per Curiam). Service as of this date by the Clerk of Court. [1003115] [NL] [Entered: 05/09/2024 10:30 AM] (3) |
| May 1, 2024 | 83 | ORDER filed granting [77] to the extent that the appellants are directed to file a bond in the district court in the amounts set forth in ECF No. [77], subject to terms and conditions deemed appropriate by the district court. (Per Curiam). Service as of this date by the Clerk of Court. [1001216] [NL] [Entered: 05/01/2024 09:54 AM] (3) |
| Apr 30, 2024 | 82 | REPLY of Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. to reply [80]. Service: 04/30/2024 by email. [1001026] [23-2032] [David Abramowitz] [Entered: 04/30/2024 02:57 PM] (18) |
| Apr 29, 2024 | 81 | Confidential Plaintiff's-Appellants' Combined Reply Brief in Support of Its Motion for an Injunction Under Rule 8 and Opposition to Appellees' Motion for Review filed by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. corresponding to Doc. No. [80]. Service: 04/29/2024 by email. [1000797] [23-2032] [Paul Hughes] [Entered: 04/29/2024 11:07 PM] (0) |
| Apr 29, 2024 | 80 | REPLY of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. to response [74]. Service: 04/29/2024 by email. [1000796] [23-2032] [Paul Hughes] [Entered: 04/29/2024 11:04 PM] (34) |
| Apr 26, 2024 | 79 | ORDER The request to expedite is granted to the extent that no later than 04/29/2024, appellants are directed to file a combined reply in support of ECF No. [71] and response to the remainder of ECF No. [77]. Any reply in support of ECF No. [77] is due no later than 05/01/2024. (Per Curiam). Service as of this date by the Clerk of Court. [1000399] [NL] [Entered: 04/26/2024 01:37 PM] (2) |
| Apr 25, 2024 | 78 | Confidential Appellees' Emergency Motion for Review, Reconsideration, or Modification of Temporary Injunction and Motion to Expedite Briefing filed by Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. corresponding to Doc. No. [77], corresponding to Doc. No. [77]. Service: 04/25/2024 by email. [1000217] [23-2032] [William Zimmerman] [Entered: 04/25/2024 07:59 PM] (0) |
| Apr 25, 2024 | 77 | MOTION of Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. to reconsider Doc. No. [73], [73], to expedite briefing schedule. Service: 04/25/2024 by email. [1000216] [23-2032] [William Zimmerman] [Entered: 04/25/2024 07:54 PM] (35) |
| Apr 25, 2024 | 76 | MOTION of Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. to waive confidentiality requirements. Service: 04/25/2024 by email. [1000212] [23-2032] [William Zimmerman] [Entered: 04/25/2024 07:24 PM] (16) |
| Apr 25, 2024 | 75 | Confidential Appellee's Confidential Opposition to Appellants' Rule 8 Motion for an Injunction Pending Appeal, Emergency Motion to Enjoin Generic Launch Pending Rule 8 Ruling, and Motion to Expedite Oral Argument filed by Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. corresponding to Doc. No. [74]. Service: 04/25/2024 by email. [1000211] [23-2032] [David Abramowitz] [Entered: 04/25/2024 06:33 PM] (0) |
| Apr 25, 2024 | 74 | RESPONSE of Appellees Lupin Pharmaceuticals, Inc., Lupin Ltd., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. to Doc No. [71], [70]. Service: 04/25/2024 by email. [1000210] [23-2032] [David Abramowitz] [Entered: 04/25/2024 06:30 PM] (119) |
| Apr 22, 2024 | 73 | ORDER ECF No. [70]'s request for a temporary injunction is granted to the extent that Lupin and Zydus are temporarily enjoined pending further order of the court. Appellees may each file a combined response to ECF Nos. [70] and [71] no later than 04/29/2024. Their responses should address Astellas' request to expedite argument. Astellas may file a single reply no later than 05/02/2024. (Per Curiam). Service as of this date by the Clerk of Court. [999186] [NL] [Entered: 04/22/2024 04:02 PM] (3) |
| Apr 22, 2024 | 72 | Confidential Motion for temporary injunction filed by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. corresponding to Doc. No. [71]. Service: 04/22/2024 by email. [998989] [23-2032] [Paul Hughes] [Entered: 04/22/2024 08:29 AM] (0) |
| Apr 22, 2024 | 71 | MOTION of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. for temporary injunction. Service: 04/22/2024 by email. [998988] [23-2032] [Paul Hughes] [Entered: 04/22/2024 08:17 AM] (94) |
| Apr 22, 2024 | 70 | MOTION of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. to enjoin generic launch pending this court's ruling on Appellant's Rule 8 motion. Service: 04/22/2024 by email. [998987] [23-2032] [Paul Hughes] [Entered: 04/22/2024 08:07 AM] (14) |
| Apr 3, 2024 | 69 | Notice from Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d. regarding conflicts with oral argument. Service: 04/03/2024 by email. [994924] [23-2032] [William Rakoczy] [Entered: 04/03/2024 03:31 PM] (2) |
| Apr 3, 2024 | 68 | Response to notice of oral argument from Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 04/03/2024 by email. [994880] [23-2032] [David Abramowitz] [Entered: 04/03/2024 02:52 PM] (1) |
| Apr 3, 2024 | 67 | Notice to Appellees Lek Pharmaceuticals, d.d., Sandoz Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.: The record of this case indicates that no Response to Notice of Oral Argument under FCR 34(e) has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [994871] [GWK] [Entered: 04/03/2024 02:39 PM] (0) |
| Mar 29, 2024 | 66 | The following conflict dates submitted by William R. Zimmerman for Lupin Pharmaceuticals, Inc. and Lupin Ltd. have been accepted by the court: 07/08/2024, 07/09/2024, 07/10/2024, 07/11/2024, 07/12/2024. [993752] [MJL] [Entered: 03/29/2024 09:36 AM] (0) |
| Mar 27, 2024 | 65 | Notice from Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 03/27/2024 by email. [993375] [23-2032] [William Zimmerman] [Entered: 03/27/2024 01:20 PM] (3) |
| Mar 27, 2024 | 64 | The following conflict date submitted by Paul Whitfield Hughes, III for Astellas Pharma, Inc., Astellas Ireland Co., Ltd. and Astellas Pharma Global Development, Inc. has been accepted by the court: 06/07/2024. [993251] [MJL] [Entered: 03/27/2024 09:26 AM] (0) |
| Mar 27, 2024 | 63 | The following conflict dates requested by William R. Zimmerman for Lupin Pharmaceuticals, Inc. and Lupin Ltd. (see Doc. No. [60]) are not accepted at this time: 07/08/2024, 07/09/2024, 07/10/2024, 07/11/2024, 07/12/2024. Please review the Guidance on Oral Argument Scheduling Conflicts for more information. [993248] [MJL] [Entered: 03/27/2024 09:24 AM] (0) |
| Mar 25, 2024 | 62 | 6 paper copies of Doc. No. [55], [53], [37] received from Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. [992994] [VDW] [Entered: 03/26/2024 11:39 AM] (0) |
| Mar 25, 2024 | 61 | Notice from Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. regarding conflicts with oral argument. Service: 03/25/2024 by email. [992813] [23-2032] [Paul Hughes] [Entered: 03/25/2024 04:07 PM] (5) |
| Mar 25, 2024 | 60 | Notice from Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 03/25/2024 by email. [992720] [23-2032] [William Zimmerman] [Entered: 03/25/2024 01:43 PM] (3) |
| Mar 21, 2024 | 59 | 6 paper copies of Doc. No. [47] received from Appellees Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Sandoz Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. [992347] [VDW] [Entered: 03/22/2024 11:20 AM] (0) |
| Mar 19, 2024 | 58 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [991465] [GWK] [Entered: 03/19/2024 10:36 AM] (1) |
| Mar 19, 2024 | 57 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [991464] [GWK] [Entered: 03/19/2024 10:36 AM] (0) |
| Mar 11, 2024 | 56 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. Service: 03/11/2024 by email. [989904] --[Edited 03/19/2024 by GWK - compliance review complete] [Paul Hughes] [Entered: 03/11/2024 06:11 PM] (515) |
| Mar 11, 2024 | 55 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. Service: 03/11/2024 by email. [989902]--[Edited 03/19/2024 by GWK - compliance review complete] [Paul Hughes] [Entered: 03/11/2024 06:02 PM] (0) |
| Mar 11, 2024 | 54 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc., Appendix, Confidential Appendix [51], [50], is not in compliance with the rules of this court (see attached). Compliant document due on 03/18/2024. Service as of this date by the Clerk of Court. [989732] [GWK] [Entered: 03/11/2024 11:43 AM] (2) |
| Mar 5, 2024 | 53 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. Service: 03/05/2024 by email. [988523] --[Edited 03/08/2024 by GWK - compliance review complete] [Paul Hughes] [Entered: 03/05/2024 05:21 PM] (42) |
| Mar 4, 2024 | 52 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc., Reply Brief [49], is not in compliance with the rules of this court (see attached). Compliant document due on 03/11/2024. Service as of this date by the Clerk of Court. [988190] [GWK] [Entered: 03/04/2024 04:21 PM] (2) |
| Mar 1, 2024 | 51 | APPENDIX FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 03/01/2024 by email. [987948] [23-2032] This document is non-compliant. See Doc No. [54] [Paul Hughes] [Entered: 03/01/2024 08:52 PM] (515) |
| Mar 1, 2024 | 50 | CONFIDENTIAL APPENDIX FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 03/01/2024 by email. [987947] [23-2032] This document is non-compliant. See Doc No. [54] [Paul Hughes] [Entered: 03/01/2024 08:50 PM] (0) |
| Feb 23, 2024 | 49 | REPLY BRIEF FILED by Appellants Astellas Pharma, Inc., Astellas Ireland Co., Ltd. and Astellas Pharma Global Development, Inc.. Service: 02/23/2024 by email. [986315] [23-2032] This document is non-compliant. See Doc No. [52] [Paul Hughes] [Entered: 02/23/2024 06:04 PM] (42) |
| Dec 15, 2023 | 48 | ORDER granting motion to extend time to file brief [45] filed by Appellants Astellas Pharma, Inc., Astellas Ireland Co., Ltd. and Astellas Pharma Global Development, Inc. The reply brief is due 02/23/2024. Service as of this date by the Clerk of Court. [970500] [LMS] [Entered: 12/15/2023 08:55 AM] (2) |
| Dec 14, 2023 | 46 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Sandoz Inc., Teva Pharmaceuticals USA, Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc., Response Brief [40], is not in compliance with the rules of this court (see attached). Compliant document due on 12/21/2023. Service as of this date by the Clerk of Court. [970336] [MMA] [Entered: 12/14/2023 02:50 PM] (2) |
| Dec 14, 2023 | 47 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellees Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Sandoz Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. Service: 12/14/2023 by email. [970451] --[Edited 12/22/2023 by MMA - Reason: compliance review complete] [William Zimmerman] [Entered: 12/14/2023 05:54 PM] (71) |
| Dec 8, 2023 | 45 | MOTION of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. to extend the time to 02/23/2024 to file brief. Service: 12/08/2023 by email. [969026] [23-2032] [Paul Hughes] [Entered: 12/08/2023 06:39 PM] (16) |
| Dec 8, 2023 | 44 | Notice of Related Case Information for Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 12/08/2023 by email. [968853] [23-2032] [Kevin Burke] [Entered: 12/08/2023 12:43 PM] (3) |
| Dec 8, 2023 | 43 | Corrected Certificate of Interest for Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 12/08/2023 by email. [968776] [23-2032] [David Abramowitz] [Entered: 12/08/2023 11:10 AM] (3) |
| Dec 8, 2023 | 42 | Notice of Related Case Information for Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 12/08/2023 by email. [968774] [23-2032] [David Abramowitz] [Entered: 12/08/2023 11:08 AM] (3) |
| Dec 8, 2023 | 41 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc., Certificate of Interest [38], is not in compliance with the rules of this court (see attached). Compliant document due on 12/15/2023. Service as of this date by the Clerk of Court. [968748] [GWK] [Entered: 12/08/2023 10:28 AM] (2) |
| Dec 6, 2023 | 40 | RESPONSE BRIEF FILED by Appellees Lupin Ltd., Lupin Pharmaceuticals, Inc., Sandoz Inc., Lek Pharmaceuticals, d.d., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Ltd.. Service: 12/06/2023 by email. [968321] [23-2032] This document is non-compliant. See Doc No. [46] [William Zimmerman] [Entered: 12/06/2023 05:57 PM] (62) |
| Dec 6, 2023 | 39 | Amended Certificate of Interest for Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 12/06/2023 by email. [968261] [23-2032] [William Rakoczy] [Entered: 12/06/2023 04:16 PM] (3) |
| Dec 6, 2023 | 38 | Amended Certificate of Interest for Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 12/06/2023 by email. [968246] [23-2032] This document is non-compliant. See Doc No. [41] [David Abramowitz] [Entered: 12/06/2023 04:02 PM] (3) |
| Nov 17, 2023 | 37 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. Service: 11/17/2023 by email. [964144]--[Edited 11/28/2023 by MMA - Reason: compliance review complete] [Paul Hughes] [Entered: 11/17/2023 01:31 PM] (118) |
| Nov 17, 2023 | 36 | Corrected Certificate of Interest for Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 11/17/2023 by email. [964143] [23-2032] [Paul Hughes] [Entered: 11/17/2023 01:28 PM] (4) |
| Nov 16, 2023 | 35 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc., Corrected Opening Brief; Certificate of Interest [14], [34], is not in compliance with the rules of this court (see attached). Compliant documents due on 11/27/2023. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [963945] [MMA] [Entered: 11/16/2023 02:53 PM] (2) |
| Nov 7, 2023 | 34 | CORRECTED OPENING BRIEF FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 11/07/2023 by email. [962122] [23-2032] This document is non-compliant. See Doc No. [35] [Paul Hughes] [Entered: 11/07/2023 10:19 PM] (118) |
| Nov 6, 2023 | 33 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc., Opening Brief [32], is not in compliance with the rules of this court (see attached). Compliant document due on 11/14/2023. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [961748] [MMA] [Entered: 11/06/2023 04:33 PM] (1) |
| Oct 27, 2023 | 32 | OPENING BRIEF FILED by Appellants Astellas Ireland Co., Ltd., Astellas Pharma, Inc. and Astellas Pharma Global Development, Inc.. Service: 10/27/2023 by email. [959836] [23-2032] This document is non-compliant. See Doc No. [33] [Paul Hughes] [Entered: 10/27/2023 07:45 PM] (117) |
| Oct 27, 2023 | 31 | Entry of Appearance for Andrew A. Lyons-Berg; Charles Seidell as counsel for Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 10/27/2023 by email. [959603] [23-2032] [Charles Seidell] [Entered: 10/27/2023 11:32 AM] (2) |
| Sep 15, 2023 | 30 | Official caption revised to remove the appellate designation of Actavis Elizabeth LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC, Huahai US Inc., Prinston Pharmaceutical Inc., Solco Healthcare U.S., LLC, Teva Pharmaceuticals USA, Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd. (see attached). Service as of this date by the Clerk of Court. [950422] [MMA] [Entered: 09/15/2023 04:02 PM] (2) |
| Aug 14, 2023 | 29 | ORDER granting motion to extend time to file brief [25] filed by Appellants Astellas Pharma, Inc., Astellas Ireland Co., Ltd. and Astellas Pharma Global Development, Inc. The opening brief is due 10/27/2023. No further extensions of time for the opening brief should be anticipated. Service as of this date by the Clerk of Court. [942625] [LMS] [Entered: 08/14/2023 09:57 AM] (2) |
| Aug 11, 2023 | 28 | REPLY of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. to response [26]. Service: 08/11/2023 by email. [942412] [23-2032] [Paul Hughes] [Entered: 08/11/2023 02:39 PM] (8) |
| Aug 11, 2023 | 27 | Notice to Appellees Actavis Elizabeth LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Aurolife Pharma LLC, Huahai US Inc., Prinston Pharmaceutical Inc., Solco Healthcare U.S., LLC, Teva Pharmaceuticals USA, Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd.: The record of this case indicates that no Entry of Appearance under FCR 47.3(b), Certificate of Interest under FCR 47.4, and/or Docketing Statement under FCR 47.6 has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Please file promptly. Service as of this date by the Clerk of Court. [942239] [MMA] [Entered: 08/11/2023 09:31 AM] (0) |
| Aug 10, 2023 | 26 | RESPONSE of Appellees Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Sandoz Inc., Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. to Doc No. [25]. Service: 08/10/2023 by email. [942178] [23-2032] [David Abramowitz] [Entered: 08/10/2023 05:34 PM] (20) |
| Aug 8, 2023 | 25 | MOTION of Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc. to extend the time to 10/27/2023 to file brief. Service: 08/08/2023 by email. [941469] [23-2032] [Paul Hughes] [Entered: 08/08/2023 02:39 PM] (15) |
| Jul 10, 2023 | 24 | Corrected Entry of Appearance for William Zimmerman; Carol Pitzel Cruz; Andrea Cheek as counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 07/10/2023 by email. [935219] [23-2032] [William Zimmerman] [Entered: 07/10/2023 05:18 PM] (2) |
| Jul 10, 2023 | 23 | Docketing Statement for the Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 07/10/2023 by email. [934958] [23-2032] [David Abramowitz] [Entered: 07/10/2023 11:15 AM] (3) |
| Jul 10, 2023 | 22 | Certificate of Interest for Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 07/10/2023 by email. [934955] [23-2032] [David Abramowitz] [Entered: 07/10/2023 11:13 AM] (4) |
| Jul 10, 2023 | 21 | Entry of Appearance for Michael J. Gaertner; Hugh S. Balsam; David B. Abramowitz; Carolyn A. Blessing; Emily L. Savas; Jonathan B. Turpin as counsel for Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 07/10/2023 by email. [934952] [23-2032] [David Abramowitz] [Entered: 07/10/2023 11:11 AM] (2) |
| Jul 6, 2023 | 20 | Note to File: The following cases are consolidated: 23-2032 (Lead) with 23-2063, 23-2089 (Members). The parties must file all documents in the lead appeal only. [934454] [ALK] [Entered: 07/06/2023 04:03 PM] (0) |
| Jul 6, 2023 | 19 | ORDER consolidating appeals 23-2032, 23-2063, and 23-2089. Appellants' opening brief is due no later than August 28, 2023. Service as of this date by the Clerk of Court. [934452] [23-2032, 23-2063, 23-2089] [ALK] [Entered: 07/06/2023 03:59 PM] (2) |
| Jul 6, 2023 | 18 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc., Entry of Appearance [17], is not in compliance with the rules of this court (see attached). Compliant document due on 07/13/2023. Service as of this date by the Clerk of Court. [934371] [JPS] [Entered: 07/06/2023 02:18 PM] (2) |
| Jul 5, 2023 | 17 | Corrected Entry of Appearance for William Zimmerman, Carol Pitzel Cruz, Andrea Cheek as counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 07/05/2023 by email. [934020] [23-2032] This document is non-complaint. See Doc. No. [18] [William Zimmerman] [Entered: 07/05/2023 12:55 PM] (2) |
| Jun 30, 2023 | 16 | Notice of Related Case Information for Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 06/30/2023 by email. [933731] [23-2032] [Kevin Burke] [Entered: 06/30/2023 06:42 PM] (3) |
| Jun 30, 2023 | 15 | Notice of Related Case Information for Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 06/30/2023 by email. [933729] [23-2032] [Paul Hughes] [Entered: 06/30/2023 05:54 PM] (3) |
| Jun 30, 2023 | 14 | Certificate of Interest for Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 06/30/2023 by email. [933728] [23-2032] [Paul Hughes] [Entered: 06/30/2023 05:52 PM] (4) |
| Jun 30, 2023 | 13 | Docketing Statement for the Appellants Astellas Ireland Co., Ltd., Astellas Pharma, Inc. and Astellas Pharma Global Development, Inc.. Service: 06/30/2023 by email. [933726] [23-2032] [Paul Hughes] [Entered: 06/30/2023 05:49 PM] (2) |
| Jun 30, 2023 | 12 | Entry of Appearance for Paul W. Hughes; Jason A. Leonard; Simon Roberts; Daniel M. Silver as counsel for Appellants Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. and Astellas Pharma, Inc.. Service: 06/30/2023 by email. [933720] [23-2032] [Paul Hughes] [Entered: 06/30/2023 05:44 PM] (2) |
| Jun 30, 2023 | 11 | Certificate of Interest for Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 06/30/2023 by email. [933704] [23-2032] [Kevin Burke] [Entered: 06/30/2023 05:25 PM] (3) |
| Jun 30, 2023 | 10 | Docketing Statement for the Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 06/30/2023 by email. [933703] [23-2032] [Kevin Burke] [Entered: 06/30/2023 05:22 PM] (2) |
| Jun 30, 2023 | 9 | Entry of Appearance for William A. Rakoczy; Deanne M. Mazzochi; Rachel Pernic Waldron; Kevin P. Burke as counsel for Appellees Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 06/30/2023 by email. [933701] [23-2032] [Kevin Burke] [Entered: 06/30/2023 05:19 PM] (2) |
| Jun 30, 2023 | 8 | NOTICE OF NON-COMPLIANCE: The submission of , Entry of Appearance [4], is not in compliance with the rules of this court (see attached). Compliant document due on 07/10/2023. Service as of this date by the Clerk of Court. [933662] [JPS] [Entered: 06/30/2023 03:36 PM] (2) |
| Jun 29, 2023 | 7 | Notice of Related Case Information for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/29/2023 by email. [933351] [23-2032] [William Zimmerman] [Entered: 06/29/2023 06:28 PM] (2) |
| Jun 29, 2023 | 6 | Certificate of Interest for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/29/2023 by email. [933350] [23-2032] [William Zimmerman] [Entered: 06/29/2023 06:27 PM] (4) |
| Jun 29, 2023 | 5 | Docketing Statement for the Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/29/2023 by email. [933349] [23-2032] [William Zimmerman] [Entered: 06/29/2023 06:25 PM] (2) |
| Jun 29, 2023 | 4 | Entry of Appearance for William Zimmerman; Carol Pitzel Cruz; Andrea Cheek as counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/29/2023 by email. [933348] [23-2032] This document is non-compliant. See Doc. No. [8] [William Zimmerman] [Entered: 06/29/2023 06:23 PM] (2) |
| Jun 29, 2023 | 3 | Documents from United States District Court for the District of Delaware. [933236] [ALK] [Entered: 06/29/2023 03:01 PM] (13) |
| Jun 26, 2023 | 2 | Notice from Appellees Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. regarding postjudgment motions. Service: 06/26/2023 by email. [932362] [23-2032] [David Abramowitz] [Entered: 06/26/2023 04:32 PM] (10) |
| Jun 16, 2023 | 1 | Appeal docketed. Received: 06/13/2023. [930642]Entry of Appearance due 06/30/2023. Certificate of Interest is due on 06/30/2023. Docketing Statement due 06/30/2023. Appellants' brief is due 08/15/2023. [MMA] [Entered: 06/16/2023 01:09 PM] (130) |
